Dilated cardiomyopathy
MONDO:0005021Cardiomyopathy which is characterized by dilation and contractile dysfunction of the left and right ventricles. It may be idiopathic, or it may result from a myocardial infarction, myocardial infection, or alcohol abuse. It is a cause of congestive heart failure.
Also known as: dilated cardiomyopathy, familial dilated cardiomyopathy, idiopathic dilation cardiomyopathy, primary dilated cardiomyopathy
130 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New heart drug AZD0233 begins first safety tests in healthy volunteers
Disease control TerminatedThis early-stage trial tested the safety of a new drug called AZD0233 in 84 healthy adults aged 18 to 50. The drug is being developed for dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Participants received either the drug or a placebo, and researc…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control TerminatedThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase: PHASE1, PHASE2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control TerminatedThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC